Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8&lt;sup&gt;+&lt;/sup&gt; T Cell Anti-Tumor Immunity. Here, CD8A is linked to neoplasm.